Dysregulation of MET signaling has been found in a variety of cancers through different mechanisms, such as activating point mutations of the MET gene, overexpression of the ligand HGF, MET gene copy number gain (MET-CNG)/amplification, and MET gene fusions [3,4]. Here, HGF is linked to cancer.